De Lorenzo F, Rubba P, Monticelli A, Cortese C, Bond H M, De Simone B, Mastranzo P, Perrotta A, Mossetti G, Cocozza S
Institute of Internal Medicine and Diseases of Metabolism, CEOS CNR, Italy.
Artery. 1993;20(2):103-14.
This study was designed to assess whether the XbaI restriction fragment length polymorphism (RFLP) for apolipoprotein B (apo B) gene could be related with a genetic predisposition to develop hyperlipidemia and atherosclerosis. Relationships between XbaI RFLP and serum cholesterol were evaluated by comparing hyperlipidemic patients with healthy controls. Statistical analysis (chi-square test) showed no significant difference in either genotype distribution or allele frequencies. Hyperlipidemic patients were then divided according to triglycerides, either above or below 200 mg/dl and XbaI genotype frequencies were measured. No significant differences in genotype distribution or allele frequencies were found. The hyperlipidemic patients were tested for the presence of arterial disease by echo-Doppler and angina questionnaire. The XbaI genotype frequencies were determined in patients with arterial disease and compared to those without evidence of disease. No significant differences were found between the two groups.
本研究旨在评估载脂蛋白B（apo B）基因的XbaI限制性片段长度多态性（RFLP）是否与发生高脂血症和动脉粥样硬化的遗传易感性相关。通过比较高脂血症患者与健康对照，评估XbaI RFLP与血清胆固醇之间的关系。统计分析（卡方检验）显示，基因型分布或等位基因频率均无显著差异。然后根据甘油三酯水平将高脂血症患者分为高于或低于200 mg/dl两组，并测量XbaI基因型频率。未发现基因型分布或等位基因频率有显著差异。通过超声多普勒和心绞痛问卷对高脂血症患者进行动脉疾病检测。测定有动脉疾病患者的XbaI基因型频率，并与无疾病证据的患者进行比较。两组之间未发现显著差异。
